DDInter1677 DDInter178
Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triamcinolone
Sipuleucel-T {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Upadacitinib
Sipuleucel-T {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Sipuleucel-T may lead to a major life threatening interaction when taken with Cladribine